Showing results (21-30 of 62) with videos related to

Sort By:
Pageof 7
Annals of Hematology|June 26, 2023
Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study GroupJulia von Tresckow, Nikola Heyl, Sandra Robrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2022
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and VenetoclaxMoritz Fürstenau, Jonathan Weiss, Adam Giza, et al.
Cancer|March 21, 2013
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemiaGeorg Hopfinger, Raymonde Busch, Natali Pflug, et al.
Cancers|October 14, 2022
CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression AnalysisAnke Schilhabel, Peter Jonas Walter, Paula Cramer, et al.
British Journal of Haematology|November 22, 2018
Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemiaOthman Al-Sawaf, Jasmin Bahlo, Sandra Robrecht, et al.
European Journal of Haematology|April 14, 2026
Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG RegistryNadine Kutsch, Rudy Ligtvoet, Sandra Robrecht, et al.
Leukemia & Lymphoma|September 19, 2022
Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and olderFlorian Simon, Adam Giza, Sandra Robrecht, et al.
American Journal of Hematology|September 9, 2014
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformationPetra Langerbeins, Raymonde Busch, Nadine Anheier, et al.
Oncoimmunology|July 30, 2016
Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiotaNatali Pflug, Sandra Kluth, Jörg J Vehreschild, et al.
Leukemia & Lymphoma|September 21, 2018
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenanceNatali Pflug, Paula Cramer, Sandra Robrecht, et al.
Pageof 7